Sjogren’s syndrome is a progressive autoimmune disease, which is caused by chronic inflammation and the lymphocytic infiltration of exocrine glands. This inflammation might happen alone, which is known as primary or with a co-morbid autoimmune condition, known as secondary Sjogren syndrome. The infiltration of the glands, usually the salivary and lacrimal gland, results in its dysfunction. In this disorder, the immune system of the body attacks its own healthy cells that produce tears and saliva. Sjogren’s syndrome is essentially characterized by dryness of the mouth, eyes, and other mucous membranes. Sjogren’s syndrome often occurs with other disorders such as rheumatoid arthritis and lupus.
COVID-19 Impact Analysis
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the Sjogren’s syndrome market
Top Impacting Factors
Development of biologics along with the strong drug pipeline has helped in boosting the growth of the Sjogren’s syndrome market.
However, lack of awareness of the availability of the medication for this syndrome can slow down the growth of the market.
Market Trends
New Product Launches to Flourish the Market
- In 2019, Ranbaxy Laboratories Limited, an Indian pharmaceutical company, launched Evoxac in the U.S. markets for Sjogren’s syndrome to treat the symptoms of dry mouth, which occurs due to a certain immune disease.
Key Benefits of the Report
- This study presents the analytical depiction of the Sjogren’s syndrome industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Sjogren’s syndrome market share.
- The current Sjogren’s syndrome market is quantitatively analyzed to highlight the growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the Sjogren’s syndrome market.
- The report provides a detailed Sjogren’s syndrome market analysis depending on competitive intensity and how the competition will take shape in coming years
Questions Answered in the Sjogren’s Syndrome Report
- Who are the leading players active in the Sjogren’s syndrome market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "Sjogren’s syndrome "?
- What is "Sjogren’s syndrome" market prediction in the future?
Key Market Segments
- By Type
- Primary Sjogren's Syndrome
- Secondary Sjogren's Syndrome
- By Application
- Oral
- Intravenous
- Subcutaneous
- By Distribution Channel
- Retail Pharmacies
- Hospitals
- Online Pharmacies
- Others
- By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals Plc
- Daiichi Sankyo Co. Ltd
- Sanofi SA
- AbbVie Inc
- Bristol-Myers Squibb Co
- Novartis AG
- Biogen Inc
- ADVANZ PHARMA Corp. Ltd
- Johnson & Johnson